BRAF and malignant colon neoplasm: To examine whether remaining mutant BRAF (BRAFV600E) is involved in recovery of ERK activation in colon cancer cells after treatment with AUY922, we knocked down BRAFV600E using a siRNA specific for the mutant form of BRAF (Figure 4B and 4C) [37].